Amzak Health

Amzak Health is a venture capital firm focused on investing across the healthcare sector, including therapeutics, devices, diagnostics, and services. Established in 2005 and based in New York, Amzak Health seeks to support companies at various stages of development, from seed to growth stages. The firm has a strong investment history, having backed over 50 healthcare companies since its inception. Amzak Capital Management, the parent company, has a broader investment strategy that includes private equity, real estate, and fixed income, primarily within the Americas. The firm has evolved from its origins in the cable television industry, which began in Canada and expanded into Latin America, to become a significant player in institutional investment across diverse sectors, with a particular emphasis on healthcare.

Uya Chuluunbaatar

Principal

Karim Maasarani

Vice President

Tony Natale

Partner

Robert Seltzer

Managing Partner

Dave Siet

Vice President

Scott E. Weiner

Partner

16 past transactions

Thryv Therapeutics

Series A in 2021
Thryv Therapeutics is a biopharmaceutical company focused on developing therapies for long QT syndrome, a genetic disorder characterized by prolonged ventricular repolarization, which can lead to life-threatening arrhythmias. The company's research centers on SGK-1, a regulator of sodium channels in heart cells, which is implicated in the overactivity associated with long QT syndrome. By targeting this kinase, Thryv aims to address the underlying causes of the disorder and improve treatment options for affected patients. Based in Laval, Canada, the company is committed to advancing its pipeline to enhance patient outcomes in this critical area of cardiovascular health.

Neuros Medical

Series B in 2021
Neuros Medical, Inc. is a neuromodulation company based in Willoughby Hills, Ohio, that specializes in developing proprietary neurostimulation therapies to address unmet medical needs for patients globally. The company’s flagship technology, Electrical Nerve Block, targets the elimination of chronic pain associated with various conditions, including neuroma, residual limb pain, chronic post-surgical pain, and chronic migraines. Additionally, Neuros Medical offers the Neuros Altius System, which features an implantable generator with an integrated rechargeable battery, a cuff electrode, and external devices designed to enhance treatment outcomes. Founded in 2008, the company aims to provide innovative solutions for chronic pain management.

Reneo Pharmaceuticals

Series B in 2020
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.

Monte Rosa Therapeutics

Series B in 2020
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Impulse Dynamics

Series D in 2019
Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure (CHF) in the United States and Europe. The company specializes in Cardiac Contractility Modulation therapy, utilizing its proprietary technology to administer non-excitatory electrical impulses that enhance cardiac performance. The Optimizer III device, which is CE marked, delivers these impulses to the ventricular septum during the myocardial absolute refractory period. Impulse Dynamics conducts clinical trials to evaluate the safety and efficacy of its treatments and collaborates with universities and hospitals for research programs. Founded in 1996 and headquartered in Willemstad, Curacao, the company also has offices in New York and Hong Kong, along with product development centers in New Jersey and Israel.

ShiraTronics

Series A in 2019
ShiraTronics is in the early stages of developing new innovative therapies to combat debilitating migraine headaches. The company is focused on commercializing novel neuromodulation technologies to treat this large unmet clinical need for patients and physicians. ShiraTronics is the first spinout from NuXcel a global medical device accelerator company.

Bellus Health

Post in 2018
Bellus Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, focused on developing therapeutics for chronic cough and other hypersensitization disorders. Its lead drug candidate, BLU-5937, is an oral small molecule antagonist of the P2X3 receptor, currently undergoing Phase II clinical trials for chronic cough and chronic pruritus. Additionally, the company is advancing KIACTA™, a novel treatment for AA amyloidosis and sarcoidosis, both rare diseases affecting renal and pulmonary functions, respectively. KIACTA™ is in the data review stage following a Phase 3 study. Bellus Health is also developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome caused by Shiga toxin-producing E. coli, with pre-clinical studies in progress. Furthermore, the company has a research-stage project aimed at treating AL amyloidosis, a condition characterized by the accumulation of amyloid proteins in various organs. Bellus Health is dedicated to addressing unmet medical needs through its innovative drug development pipeline.

Miach Orthopaedics

Series A in 2018
Miach Orthopaedics is a medical device company that develops bio-engineered surgical implants to facilitate new tissue growth. The company's product is the Bridge-Enhanced ACL Repair technology as a viable alternative to conventional ACL reconstruction for patients who have withstand an anterior cruciate ligament injury. Miach Orthopaedics was founded on 2016 and is headquartered in Westborough, Massachusetts.

MEI Pharma

Post in 2018
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company’s clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.

Eidos Therapeutics

Series B in 2018
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.

GTx

Post in 2017
GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.

Inspire Medical Systems

Series F in 2016
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company also develops a novel, a closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. Inspire Medical Systems, Inc. was founded in 2007 and is headquartered in Golden Valley, Minnesota.

Essential Medical

Series B in 2016
Essential Medical, Inc. is a medical device company based in Malvern, Pennsylvania, that specializes in developing femoral artery vascular closure devices. Founded in 2010, the company focuses on sealing femoral punctures that occur after diagnostic and interventional cardiac catheterization procedures. Essential Medical has created two primary closure devices, including MANTA, which is specifically designed to address large bore punctures ranging from 10 to 24 French. These devices are particularly relevant for procedures such as transcatheter aortic valve replacement (TAVR), abdominal aortic aneurysm repair (AAA/PVAR), and balloon aortic valvuloplasty (BAV). The innovations from Essential Medical aim to fulfill a significant need in interventional cardiology by providing efficient closure solutions that minimize complications for patients. Since October 2018, the company operates as a subsidiary of Teleflex Incorporated.

Assurance Operations Corp.

Acquisition in 2015
Assurance Operations Corp. is a full-service engineering and manufacturing company of custom metal fabricated parts and stamping. AOC specializes in the design, development, testing, program management, and production of custom industrial packaging and material handling, and stamping of light and heavy aluminum, stainless steel, and steel parts.

KEW

Series B in 2014
KEW, Inc. is a genomic testing company focused on personalized cancer treatment. Based in Cambridge, Massachusetts, it offers a range of services that assist oncologists in making informed treatment decisions based on the genetic characteristics of individual tumors. KEW utilizes its proprietary CANCERPLEX testing service, which includes various panel options such as CANCERPLEX FP for full genomic analysis, CANCERPLEX TS for specific tumor types, and CANCERPLEX TX for FDA-approved targeted therapies. By providing these genomic insights, KEW aims to enhance the precision of oncology care, enabling healthcare providers to deliver tailored therapies that align with each patient's unique genetic profile. The company was founded in 2009 and has evolved to support community oncology practices in optimizing patient care through advanced genomic information.

Marbles: The Brain Store

Private Equity Round in 2014
Marbles: The Brain Store is a specialty retailer focused on providing a diverse range of brain-building products, including games, puzzles, books, and educational toys. The store is designed to offer a hands-on shopping experience for families, allowing customers to explore and try unique items that promote cognitive development. Through interactive in-store experiences and online product demonstrations, Marbles helps individuals of all ages enhance critical thinking, memory, coordination, visual perception, and word skills. The emphasis on high-quality and engaging products positions Marbles as a destination for those seeking to nurture their mental acuity in an enjoyable manner.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.